CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Metronidazole and Rifampindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00182429
NCT00182429Phase 3Completed

Prospective, Randomized Study of Oral Metronidazole vs. Oral Metronidazole and Rifampin for Treatment of Clostridium Difficile-associated Diarrhea (CDAD)

McMaster University·interventional·Posted Sep 16, 2005·Updated Aug 15, 2018

In Brief

A Phase 3 clinical trial evaluating Metronidazole and Rifampin for Clostridium Enterocolitis and 4 related conditions. Completed, across 4 sites.

Detailed Summary

What is the difference between the use of one drug (Oral Metronidazole) versus the use of this same drug combined with another drug (Rifampin) in treatment of bacteria and infection-associated diarrhea in patients? This infection is an important cause of morbidity and mortality in both the community and hospitals, and the leading cause of hospital and chronic facility-acquired diarrhea. Research is important for the treatment of this infection. Patient care with use of two medication treatment regimens will be studied.

Study Details

Timeline

Phase 3CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 16, 2005
Enrollment StartFeb 1, 2004
Primary CompletionApr 30, 2005
Study CompletionDec 31, 2005
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 20.8 years ago

Interventions

Metronidazole and Rifampindrug